

Old Line Capital Partners

CONTACT

Jerry Schepers
Old Line Capital
443.255.7483
jerry@oldlinecap.com
oldlinecap.com

FOR IMMEDIATE RELEASE

Old Line Capital Invests in KaloCyte *Press release*

Columbia, Md., July 20, 2020 – Old Line Capital Partners (www.oldlinecap.com) announced today that they have made a significant investment in KaloCyte, Inc., (www.kalocyte.com) to extend the research and development of its break-through human blood substitute ErythroMer - a dried, bio-inspired artificial red blood cell (RBC).

“KaloCyte is the exact type of company we look for at Old Line Capital,” stated Jerry Schepers, Old Line Capital’s General Partner and lead for the KaloCyte deal. “The KaloCyte team has the leadership, experience, and expertise necessary to bring ErythroMer to fruition and address the many problems and limitations with existing RBC supply-chains. ErythroMer is innovative, disruptive, and impactful – if successful, ErythroMer will save countless lives. We are excited to be a partner, providing critical capital to continue KaloCyte’s exciting work”.

“We are thrilled to have Old Line Capital as an investor in KaloCyte and our development of ErythroMer,” said Elaine Haynes, president and chief executive officer of KaloCyte. “Old Line Capital is known for selecting unique and innovative products developed in the Mid-Atlantic region and then working with the company to bring that product to market – a perfect fit as we advance the technology and commercialization of ErythroMer.” Haynes added that the COVID-19 pandemic highlights the tenuous nature of our nation’s blood supply making KaloCyte’s mission to develop an RBC substitute to address unmet needs even more critical.

About KaloCyte

KaloCyte, Inc., a pre-clinical stage healthcare biotech startup company, recently relocated to the University of Maryland, Baltimore (UMB) as an Affiliate of the UM BioPark. KaloCyte’s offices and labs are sited within the new UM School of Medicine’s Center for Blood Oxygen Transport and Hemostasis (CBOTH) directed by Allan Doctor, MD (KaloCyte Co-Founder and CSO). KaloCyte was founded in 2016 by a distinguished team of researchers in physiology, bioengineering, and trauma care. KaloCyte has demonstrated proof of concept for ErythroMer, a dried, bio-inspired artificial red blood cell envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte has an exclusive license for the technology from Washington University in St. Louis, and is supported by nearly \$7M in federal awards and investor funding.

About Old Line Capital Partners

Old Line Capital is a venture capital firm focused on the financing and development of early stage technology startups in Maryland and the broader mid-Atlantic region.